Navigation Links
PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
Date:11/20/2008

BOSTON, Nov. 20 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it has opened an office in Lima, Peru to provide regulatory consulting and clinical research capabilities. With the addition of the Peru office, PAREXEL now has locations throughout five important biopharmaceutical centers in Latin America, which also include Argentina, Brazil, Chile, and Mexico. This expansion further strengthens the Company's position as one of the largest biopharmaceutical services providers in this emerging region for clinical development.

"PAREXEL has had a presence in Latin America since 1997, and a long-term commitment to providing clients with high quality services in the region. Due to the increasing globalization of clinical research, client demand for our capabilities in Latin America has been steadily increasing, and over the last seven years PAREXEL has experienced double-digit growth in the region. Peru is a key growing market in Latin America, with approximately 28 million people. The opening of our Peru office marks a significant opportunity for clients to further expand their clinical development programs throughout Latin America," said Josef H. von Rickenbach, Chairman and Chief Executive Officer of PAREXEL. "Our experts in Latin America manage complex clinical trials on a regional and worldwide scale. Included among the broad array of services we provide, we are helping clients to navigate regulatory environments, identify qualified investigators, and access diverse patient populations throughout the region."

Capabilities provided by PAREXEL's Latin American locations include regulatory advice for clinical development, as well as a broad range of services including project management, site management, data management, medical affairs, biostatistics, and bioanalysis for the conduct of Phase II-IV studies. PAREXEL's clinical logistics team in Latin America, with in-depth expertise in import and export regulations, coordinates multinational logistics and helps clients effectively manage global clinical trial supply requirements. PAREXEL's Latin American locations offer extensive late phase development capabilities including observational studies, patient registries, outcomes research, and expanded access programs.

For more information about PAREXEL's global Clinical Research Services, visit http://www.parexel.com/clinical_research.html.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Contacts:
    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409
    Email: Jennifer.Baird@PAREXEL.com

    Rebecca Passo
    SHIFT Communications
    Tel: +617-779-1817
    Email: rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
7. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
8. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
9. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
10. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... locations throughout Arkansas that offers insurance and financial preparation services, is providing an ... Rock City Rescue organization. , Rock City Rescue is a locally recognized nonprofit ...
(Date:10/13/2017)... ... , ... While it’s often important to take certain medications during the night, ... has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX ... eliminates the need to turn on a light when taking medication during the night, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
Breaking Medicine News(10 mins):